Navigation Links
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard - IPM) to treat advanced sarcoma patients was presented at the European Society of Medical Oncology (ESMO) meeting held July 5-8, 2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/II Study of IPM (ZIO-201) In Advanced Sarcoma," was presented by Rashmi Chugh, MD, a Principal Investigator from the University of Michigan, Ann Arbor, Michigan.

The trial has now enrolled 39 patients and this presentation reports on the first 10 evaluable patients. Of these 10 heavily pretreated patients (median 4 prior regimens), 1 has a partial response (21 weeks and ongoing) and 4 have stable disease. Of these 5 patients, 2 had progressed through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients.

"Ifosfamide is one of the few effective standard therapies available for most sarcomas," commented Dr. Chugh. "Having a novel drug that could offer the benefits of high-dose ifosfamide without the debilitating side effects, particularly the bone marrow suppression and neurotoxicity, would be of great benefit in the treatment of this disease. We are enthusiastic about these early results and we look forward to further elucidating the overall impact of ZIO-201 in this setting."

The Company expects to report more complete data at upcoming medical meetings, including the 14th European Cancer Conference (ECCO) taking place in Barcelona from September 23-27, 2007.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
(Date:9/30/2014)... Sept. 30, 2014  HealthLoop® released an app version ... in iOS 8 and allows people to share medical ... harnesses native iOS technologies to enhance the HealthLoop experience ... connection with their doctors between visits. ... data they collect is exciting," says HealthLoop founder Dr. ...
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional is ... and tissue for a wide range of away ... its product lines in healthcare, including hospitals, long-term ... Professional is introducing its healthcare products and solutions ... understands the importance of infection control in the ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... Dec. 2, 2010 Palatin Technologies, Inc. (NYSE Amex: ... Amex LLC (the "Exchange"), advising Palatin that it is not ... standards under Section 1003 of the Exchange,s Company Guide. ... Palatin was not in compliance with Section 1003(a)(iii) of the ...
... Group is reporting a 35% surge in patients booking in ... the month before Christmas. Many patients are ... made before they return to work in the New Year. ... Breast enlargement , Nose Reshaping, and Liposuction. Lisa ...
Cached Medicine Technology:Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 2Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 3The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas 2
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... 2014 Glycodrive , one of ... to help maximize lean, strong muscle growth with a ... of glucose has caught the attention of Shane Michaels, ... behind Glycodrive is to help the body use carbohydrates ... “Carbs are essential in the muscle-building process, and Glycodrive ...
(Date:9/30/2014)... VisitandCare.com reports that revenue ... up more than 79 percent in 2014, marking five ... reported total revenue tripled for its entirety of partnered ... strategy has allowed them to partner with plastic ... comfort and privacy — with state-of-the-art surgical atmospheres aimed ...
(Date:9/30/2014)... A group of Americans is headed to ... that, left unchecked, could create a catastrophic, global pandemic. No, ... Africa. John Rogers, the Executive Director the Eugene Bell Foundation ... a disease most think mankind conquered long ago: tuberculosis. , ... is on the comeback in several countries - what’s especially ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Use of estrogen alone did not increase lung cancer ... online August 13 in The Journal of the ... Health Initiative (WHI) trial, which consisted of several clinical ... previous hysterectomy taking combined estrogen plus progestin therapy had ...
... Reporter , FRIDAY, Aug. 13 (HealthDay News) -- When John D,Amato ... bottle of ibuprofen on the living room floor -- and one ... the pain-reliever container off the coffee table -- where D,Amato had ... pills. "My heart dropped through the floor," he said of ...
... influential medical centers to adopt electronic medical records helps ... Management Insights feature in the current issue of ... for Operations Research and the Management Sciences (INFORMS)., "Social ... Medical Records in U.S. Hospitals" is by Corey M. ...
... over the past 25 years has not translated into ... problems with study design and interpretation, as well as ... 12 in The Journal of the National Cancer ... defines a biomarker as "a characteristic that is objectively ...
... hereditary cancer syndrome may have a role in the regulation of ... the August 15 issue of Genes & Development , a ... called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls ... two major types of liver cells. "We found that ...
... HealthDay Reporter , THURSDAY, Aug. 12 (HealthDay News) ... new study finds that many heart patients aren,t all ... in Australia discovered that patients more often preferred boring ... pressure. "Fifty grams of dark chocolate [roughly one ...
Cached Medicine News:Health News:Estrogen not associated with lung cancer incidence and mortality among postmenopausal women 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 3Health News:Speed electronic medical record adoption via key medical centers, says Management Science 2Health News:The cancer biomarker conundrum: Too many false discoveries 2Health News:Merlin protein found to control liver stem cells, prevent tumor development 2Health News:Many Patients Say 'No' to Chocolate As Medicine 2Health News:Many Patients Say 'No' to Chocolate As Medicine 3
Low temp, micro fine tip, patented Aaron RAM cauteries....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: